Lewis Fermaglich

Drugs and biologics receiving FDA orphan drug designation: an analysis of the most frequently designated products and their repositioning strategies

Expert Opinion on Orphan Drugs · 2022 · Last of 4 authors · 14 citations

A comprehensive study of the rare diseases and conditions targeted by orphan drug designations and approvals over the forty years of the Orphan Drug Act

Orphanet Journal of Rare Diseases · 2023 · First of 2 authors · Corresponding